GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00716170|
Recruitment Status : Completed
First Posted : July 16, 2008
Last Update Posted : November 28, 2013
|Condition or disease||Intervention/treatment|
|Type 2 Diabetes Mellitus||Biological: Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)|
Patients with T2DM are not able to suppress their secretion of glucagon after a meal or after oral ingestion of glucose. Patients actually respond with pathological high plasmaglucagon concentrations to these stimuli. Previous studies have shown that postprandial hyperglucagonemia results in increased hepatic glucose production and therefore contributes significantly to the hyperglycemia characterizing these patients.
Recently we have shown that patients with T2DM exhibit a normal suppression of glucagon secretion following an adjustable intravenous (iv) glucose challenge mimicking the glucose excursion following a 50-g oral glucose tolerance test (OGTT) with the latter resulting in lack of glucagon suppression. Why this difference? A possible explanation could be that the oral administration stimulates intestinal factors resulting in a differentially glucagon response to the two similar glucose excursions. We wish to establish whether GIP, GLP-1 and/or GLP-2 are responsible for the inappropriate glucagon suppression following OGTT and meals in patients with T2DM.
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Official Title:||The Role of GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia|
|Study Start Date :||July 2008|
|Primary Completion Date :||July 2009|
|Study Completion Date :||July 2009|
Patients with type 2 diabetes mellitus
Biological: Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)
Day A: Oral glucose tolerance test (50g glucose)
Day B: Isoglycemic intravenous (iv) glucose infusion
Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)
Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)
Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)
Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E.
- Plasma glucagon responses [ Time Frame: 3 hours ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00716170
|Department of Endocrinology J, Herlev Hospital|
|Herlev, Denmark, 2730|
|Study Chair:||Tina Vilsbøll, MD DMSc||Herlev Hospital|
|Study Director:||Filip K Knop, MD PhD||Gentofte Hospital|